HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, T. Articles by Sasano, H. Search for Related Content PubMed PubMed Citation Articles by Suzuki, T. Articles by Sasano, H.

Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan
¹ Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan
² Department of Surgery, Tohoku University School of Medicine, Sendai, Japan
³ Department of Surgery, Tohoku Kosai Hospital, Sendai, Japan
⁴ Department of Molecular Medical Technology, Tohoku University School of Medicine, Sendai, Japan

(Requests for offprints should be addressed to T Suzuki; Email: t-suzuki{at}patholo2.med.tohoku.ac.jp)

A Inoue is now at InfoGenes Co. Ltd, Tsukuba, Japan

Early growth responsive gene 3 (EGR3) is a zinc-finger transcription factor and plays important roles in cellular growth and differentiation. We recently demonstrated estrogen-mediated induction of EGR3 in breast carcinoma cells. However, EGR3 has not yet been examined in breast carcinoma tissues and its significance remains unknown. Therefore, in this study, we examined biological functions of EGR3 in the breast carcinoma by immunohistochemistry, in vitro study, and nude mouse xenograft model. EGR3 immunoreactivity was detected in carcinoma cells in 99 (52%) out of 190 breast carcinoma tissues and was associated with the mRNA level. EGR3 immunoreactivity was positively associated with lymph node status, distant metastasis into other organs, estrogen receptor , or EGR3 immunoreactivity in asynchronous recurrent lesions in the same patients, and was negatively correlated with tubule formation. EGR3 immunoreactivity was significantly associated with an increased risk of recurrence and adverse clinical outcome by both uni- and multivariate analyses. Egr3-expressing transformant cell lines derived from MCF-7 Tet-Off cells (Eg-10 and Eg-11) significantly enhanced the migration and invasion properties according to the treatment of doxycyclin, but did not significantly change the cell proliferation. Moreover, Eg-11 cells injected into athymic mice irregularly invaded into the adjacent peritumoral tissues, although Clt-7, which was stably transfected with empty vector as a control, demonstrated a well-circumscribed tumor. Eg-11 cells were significantly associated with invasive components and less tubule formation in the xenograft model. These results suggest that EGR3 plays an important role in estrogen-meditated invasion and is an independent prognostic factor in breast carcinoma.

This article has been cited by other articles:

				H. Niikawa, T. Suzuki, Y. Miki, S. Suzuki, S. Nagasaki, J. Akahira, S. Honma, D. B. Evans, S.-i. Hayashi, T. Kondo, et al. Intratumoral Estrogens and Estrogen Receptors in Human Non-Small Cell Lung Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4417 - 4426. [Abstract] [Full Text] [PDF]